Birchview Capital, LP Alkermes Plc. Transaction History
Birchview Capital, LP
- $117 Million
- Q4 2024
A detailed history of Birchview Capital, LP transactions in Alkermes Plc. stock. As of the latest transaction made, Birchview Capital, LP holds 50,000 shares of ALKS stock, worth $1.68 Million. This represents 1.23% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$1.68 Million
Previous $1.4 Million
2.79%
% of portfolio
1.23%
Previous 1.29%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
375Shares Held
166MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$976 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$620 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$411 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$296 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$253 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.51B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...